– USA, MA – Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the appointment of Michael Wyzga as SVP and CFO.
“Michael’s financial expertise combined with his proven ability to execute strategic and operational objectives will be invaluable to the Company,” said CEO, Dr. Richard Peters. “We are looking forward to Michael’s contributions as we continue to pursue our vision of a future free from neurodegenerative disease.”
About Michael Wyzga
Mr. Wyzga has more than a decade of experience in healthcare finance. He joins the Company after eight years at Needham & Company, a privately held, full-service investment bank that focuses exclusively on growth companies, where he served as VP in the Healthcare Investment Banking group. While at Needham, Mr. Wyzga provided strategic and financial advice to clients across the life sciences sector and executed numerous initial public offerings, follow-on offerings, private placements, M&A, and other transactions. Before this role, Mr. Wyzga was part of the Healthcare Corporate and Investment Banking group at Citigroup.
“Joining Yumanity provides the opportunity to be part of a company that has the potential to truly address the challenges of neurodegenerative diseases,” said Mr. Wyzga. “I am looking forward to working with the exceptional team at Yumanity as we approach a key development milestone for our lead program YTX-7739 and advance our pipeline.”
Mr. Wyzga earned his B.A. in Finance from Lehigh University and an M.B.A. from the S.C. Johnson School of Business at Cornell University.
About Yumanity Therapeutics
Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company’s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson’s disease. Yumanity’s drug discovery platform is designed to enable the Company to rapidly screen for potential disease-modifying therapies by overcoming the toxicity of misfolded proteins in neurodegenerative diseases. Yumanity’s pipeline consists of additional programs focused on Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease.
For more information, please visit www.yumanity.com.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.